Company · BIIB
Biogen
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
12
12 still marketed
Novel approvals
10
Approvals since 2021
12
Originals and new uses
Phase 3 trials
94
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Zurzuvae new use Priority reviewNov 13, 2026
- Spinraza new use OrphanMar 27, 2026
- Skyclarys new use OrphanDec 20, 2024
- Tofidence approved Sep 29, 2023
- Zurzuvae approved NovelPriority reviewAug 4, 2023
- Qalsody approved NovelAccelerated approvalPriority reviewOrphanApr 25, 2023
- Skyclarys approved NovelPriority reviewOrphanFeb 28, 2023
- Tecfidera new use Feb 10, 2023
- Vumerity new use Feb 10, 2023
- Aduhelm new use Feb 8, 2023
Drugs in development (8)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- LitifilimabBIIB059Phase 35 trials
Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic
- SalanersenBIIB115Phase 33 trials
Biogen · Muscular Atrophy, Spinal, Spinal Muscular Atrophy
- DNL151BIIB122Phase 22 trials
Denali Therapeutics Inc. · Parkinson Disease
- BGC101autologous EnEPC preparationPhase 21 trial
Biogen · Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
- BIIB091Phase 21 trial
Biogen · Relapsing Forms of Multiple Sclerosis
- BIIB147Phase 21 trial
Biogen · Amyotrophic Lateral Sclerosis
- DiranersenISIS 814907, BIIB080Phase 21 trial
Biogen · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Recruiting Phase 3 trials
Largest first.
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT06935357 · 454 participants (planned) · Start May 8, 2025 · Primary completion May 31, 2027
Drug: Felzartamab; Placebo · For: Immunoglobulin A Nephropathy (IgAN)
Sites: Little Rock, Arkansas; Apple Valley, California; Carlsbad, California · 265 sites in all
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT06962800 · 180 participants (planned) · Start May 22, 2025 · Primary completion Jan 28, 2030
Drug: Felzartamab; Tacrolimus and 1 more · For: Primary Membranous Nephropathy
Sites: Huntsville, Alabama; Fresno, California; Los Angeles, California · 117 sites in all
BiogenBiogen (BIIB)
NCT07444476 · 90 participants (planned) · Start Sep 8, 2026 · Primary completion Jun 23, 2028
Drug: Salanersen · For: Spinal Muscular Atrophy
Sites: Palo Alto, California; Boston, Massachusetts; Norfolk, Virginia · 12 sites in all
- A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene AbeparvovecPivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT07444450 · 42 participants (planned) · Start Oct 31, 2026 · Primary completion Jul 27, 2029
Drug: Salanersen · For: Muscular Atrophy, Spinal
Sites: Flower Mound, Texas
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT07221669 · 30 participants (planned) · Start Apr 28, 2026 · Primary completion Nov 28, 2028
Drug: Salanersen · For: Muscular Atrophy, Spinal
Sites: Chicago, Illinois; Flower Mound, Texas; Norfolk, Virginia · 14 sites in all
Marketed drugs (12)
Newest FDA action first.
- Zurzuvae Zuranolone · 2023
- Tofidence Tocilizumab-Bavi · 2023
- Skyclarys Omaveloxolone · 2023
- Spinraza Nusinersen Sodium · 2016
- Tysabri Natalizumab · 2004
- Vumerity Diroximel Fumarate · 2019
- Aduhelm Aducanumab-Avwa · 2021
- Tecfidera Dimethyl Fumarate · 2013
- Avonex Interferon Beta-1a · 1996
- Plegridy Peginterferon Beta-1a · 2014
- Qalsody Tofersen · 2023
- Zinbryta Daclizumab · 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.